- Small-Cap Stock Portfolio <span style=' color: rgb(255, 255, 255); text-shadow: 2px 2px 1px #1b1b1b; font-size: 40px;'>Pressure BioSciences<br /><em style='font-weight:400; font-size:34rem;'> (OTCQB: PBIO)</em></span><br /> -

Pressure BioSciences

 Fact Sheet

Pressure BioSciences, Inc. (OTCQB: PBIO) develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6 billion life sciences sample preparation market. Our products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or PCT) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to safely and reproducibly control bio-molecular interactions. To date, we have installed over 250 PCT systems in approximately 160 sites worldwide. There are over 100 publications citing the advantages of the PCT platform over competitive methods, many from key opinion leaders. Our primary application development and sales efforts are in the biomarker discovery and forensics areas. Customers also use our products in other areas, such as drug discovery & design, bio-therapeutics characterization, soil & plant biology, vaccine development, histology, and counter-bioterror applications.

Investment HighlightsValue Proposition
Company Name Pressure BioSciences
Market/Symbol OTCQB: PBIO
Industry Biotech Services
Recent Price
Market Cap$5.73M
Shares Outstanding$1.75M
Avg. Daily Vol. (3m)11,833
Price/Cash Flow N/A
As of Mar. 18, 2019
*Source: QuoteMedia



Recent Company Videos

Pressure BioSciences: Game-Changing Technology for the $6B Life Sciences Sample Preparation Market

Jun. 13, 2018

Pressure BioSciences Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide ...

Investment Highlights

  • ISS high-pressure optical cell integrates with PBIO automated high-pressure instrument
  • Combination results in unique analytical system with potential to significantly improve and enhance biopharmaceutical drug discovery and developmen

  • Consumable sales increased by 158%, from $32,811 in 3Q16 to $84,594 in 3Q17

  • Acquisition drives PBIO into several important areas in biological research and manufacturing

  • CE marking will allow PBIO to market its products freely in 31 countries across Europe

  • PCT technology uses hydrostatic pressure to break open cells, which may result in new discoveries not previously possible with current sample-preparation methods

100+ publications in peer-reviewed journals confirming the advantages of PCT technology over current sample-preparation methods

Value Proposition

PBIO’s patented PCT platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis) of cells and tissues from human, animal, plant, and microbial sources. The Company has sold approximately 300 instrument systems worldwide to leading academic, government, biotech, and pharma laboratories. Additionally, there have been over 100 journal articles and peer-reviewed publications on the advantages of PCT technology. In March 2017, the Company announced an expansion of the Company’s sales and marketing team, and in December 2017, the company announced acquisition of BaroFold, which specializes in high-pressure technologies; these positive changes should begin to show strong sales increases going forward. PBIO CEO Richard T. Schumacher is a serial entrepreneur who has had substantial success in founding, growing, and operating biotech and pharma businesses; as president and co-founder of Panacos Pharma, in seven years he helped move the company from a struggling start-up to a $700 million market-cap company. Relative to sales potential, if PBIO can capture just 25% of the market opportunity in mass spectrometry, then we believe it could lead to $75 million in device sales and $36 million in annual recurring revenue. Additional long-term opportunities for PCT exist.

Pressure BioSciences Latest News

Latest Investor Presentation

Latest Investor Presentation


PBIO Research

PBIO’s patented PCT platform uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels (up to 90,000 psi) to safely and conveniently control the rupture (lysis)… Read More

Mar. 09, 2018

For over two decades RedChip Companies has been writing research on small-cap stocks. RedChip was the first to put independent research coverage on Starbucks in 1992. Our research analysts, CFAs, include financial models and target prices based on industry competitors. Our analysts cover dozens of stocks with a focus on healthcare, technology, social media, and consumer goods.

RedChip Companies research reports are distributed to 60,000 opt-in retail, institutional, and accredited investors.

Receive PBIO Email Alerts

*By entering your information you agree to our privacy policy.

"I work with many of the companies that would be RedChip companies. And we certainly ascribe to the same view that the RedChip Companies do, which is Discovering Tomorrow's Blue Chips Today."

  • Bob McCooey, Senior Vice President, NASDAQ Stock Market